GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound I-33 [US20220081429]
Compound class:
Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026) in which it is desribed as an immunomodulator. The structure is claimed in patent US20220081429 (Artax Biopharma) as an inhibitor of the protein-protein interaction between the CD3 component of the T cell receptor (TCR) and non-catalytic (SH3.1) region of tyrosine kinase adaptor protein (Nck; NCK1, NCK2) [1]. This mechanism is proposed to modulate TCR activation driven by weak avidity self antigens in autoimmune diseases [2]. Artax Biopharma's only disclosed candidate in this class is AX-158, so we surmise that zecontimod is the INN match for AX-158.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 3-[[4-(4-fluorophenyl)-3-(pyrrolidin-1-ylmethyl)-2H-chromen-6-yl]oxy]propanoic acid |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 13816 | zecontimod |
Synonyms ![]() |
| compound I-33 [US20220081429] |
Database Links ![]() |
|
| Search Google for chemical match using the InChIKey | XXARLKNSPVBUSQ-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | XXARLKNSPVBUSQ |
| Search PubMed clinical trials | zecontimod |
| Search PubMed titles | zecontimod |
| Search PubMed titles/abstracts | zecontimod |
| UniChem Compound Search for chemical match using the InChIKey | XXARLKNSPVBUSQ-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | XXARLKNSPVBUSQ-UHFFFAOYSA-N |